EVAL-APIVIGIE: Evaluation of the API-VIGIE Monitoring System: Program to Reduce Emergency Visits for Severe Paroxysmal Alcoholism

Sponsor
Centre Hospitalier Arras (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05173116
Collaborator
F2RSM Psy (Hauts-de-France Regional Federation for Research in Psychiatry and Mental Health) (Other)
488
1
17.9
27.2

Study Details

Study Description

Brief Summary

The study was designed to evaluate the APIVIGIE program use at CH d'Arras. The objective of this program is to reduce repeated visits by the same patient to the emergency room for Alcoholism Severe Paroxysmal

Condition or Disease Intervention/Treatment Phase
  • Other: Medical Outcomes Study Short Form 36 (SF 36)
  • Other: observationnal study

Detailed Description

In France, between 10% and 30% of emergency room admissions are linked to problematic alcohol consumption. This considerable weight of alcohol-related problems in the current problematic of emergencies is largely unknown and can lead to blockages in emergencies.

For acute intoxication requiring emergency care, 80% of admissions concern people dependent on alcohol. Here again, this crucial clinical notion is largely ignored: when a patient in a state of intoxication arrives in the emergency room, this should not be considered as a banal and one-off event, it is necessary to put in place a care, if necessary, of addiction.

Supported by a call for projects from the Hauts-de-France Regional Health Agency, the Addictions Service of the Arras Hospital is setting up a monitoring system called APIVIGIE.

APIVIGIE program is offered to patients who present to the emergency room for a diagnosis of API after an evaluation by the liaison team of the addiction service. If the patient agrees to be part of the program, he will receive a resource card with the APIVIGIE phone number to contact if necessary.

The link will be maintained with the Addictology Care, Support and Prevention Center (CSAPA) for a period of 6 months, by telephone consultations, or by video-consultations or face-to-face consultations.

Study Design

Study Type:
Observational
Anticipated Enrollment :
488 participants
Observational Model:
Cohort
Time Perspective:
Other
Official Title:
Evaluation of API-VIGIE Monitoring System: Program to Reduce Emergency Visits for Severe Paroxysmal Alcoholism
Anticipated Study Start Date :
Feb 1, 2022
Anticipated Primary Completion Date :
Feb 1, 2023
Anticipated Study Completion Date :
Aug 1, 2023

Arms and Interventions

Arm Intervention/Treatment
prospective study

API-VIGIE program adult participant who agreed to participate in the study

Other: Medical Outcomes Study Short Form 36 (SF 36)
completion of questionnaire quality of life SF 36 (inclusion, Month 3, Month 6).

retrospective study

Any stay for adults patients in the emergency room of the ARRAS hospital for API during the period covered (from 1 year before to 1 year after the installation of the APIVIGIE program) (main diagnosis or associated with an API (F10.0 according to the ICD-10 classification used by Department of Medical Information)

Other: observationnal study
data collection

Outcome Measures

Primary Outcome Measures

  1. Number of visits to the Emergency Reception Service for Significant Paroxysmal Alcoholics [during 2 years]

    1 year before implementation of the program and up to 1 year after implementation of the program

Secondary Outcome Measures

  1. weekly consumption of alcoholic beverages [Inclusion , Visit 2 (Month 3) and visit 3 (Month 6)]

  2. weekly consumption of other substances (cannabis, other substances) [Inclusion , Visit 2 (Month 3) and visit 3 (Month 6)]

  3. Quality of life score, measured by the Medical Outcomes Study Short Form 36 (SF-36) health scale score. [Inclusion , Visit 2 (Month 3) and visit 3 (Month 6)]

    SF 36 giving a score from 0 to 100. More higher score, more better quality of life.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patient 18 years or older;

  • Participant at API-VIGIE program.

Exclusion Criteria:
  • Patient's opposition to participating in the research;

  • Persons under legal protection (under tutorship or curatorship);

  • Person deprived of liberty;

  • Pregnant or breastfeeding women.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Dominique LEJEUNE Arras France

Sponsors and Collaborators

  • Centre Hospitalier Arras
  • F2RSM Psy (Hauts-de-France Regional Federation for Research in Psychiatry and Mental Health)

Investigators

  • Principal Investigator: Dominique LEJEUNE, M.D, Centre Hospitalier Arras

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Centre Hospitalier Arras
ClinicalTrials.gov Identifier:
NCT05173116
Other Study ID Numbers:
  • 2020-08
First Posted:
Dec 29, 2021
Last Update Posted:
Dec 29, 2021
Last Verified:
Nov 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Centre Hospitalier Arras
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 29, 2021